Endo International has appointed Terrance J. Coughlin as executive vice president and chief operating officer (COO) and has named Tony Pera as president, Par Pharmaceutical, Endo's US generics operating company. Both appointments are effective as of November 1, 2016.
Most recently, Mr. Coughlin served as vice president, operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo's acquisition of Par in September 2015, Mr. Coughlin was the COO of Par Pharmaceutical Companies, Inc. Prior to joining Par, Mr. Coughlin held a number of leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited, latterly as the president and chief executive officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. Prior to this, Mr. Coughlin had the overall responsibility for Glenmark's North American, Western European and Eastern European generics businesses as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as senior vice president at Dr. Reddy's Laboratories. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company.
Most recently, Mr. Pera served as chief commercial officer (CCO) of Par Pharmaceutical. He joined Par in February 2014 as part of Par's acquisition of JHP Pharmaceutical, where he held a similar position. As CCO, Mr. Pera was responsible for all sales, marketing, pricing,and customer operations functions for Par. Prior to JHP and Par, Mr. Pera was senior vice president of supply chain management for AmerisourceBergen (ABC), a US pharmaceutical wholesaler, for approximately five years. Prior to ABC, he held numerous senior leadership positions with generic drug companies including APP (now Fresenius Kabi), Bedford Laboratories, and LyphoMed. Mr. Pera started his career as a sales representative for the parenteral products division of Baxter. He currently serves as the secretary-treasurer of the board of directors for the Generic Pharmaceutical Association.